lungpacer.comCrawled Oct 25, 2026
The page presents clinical research and published evidence on diaphragm stimulation using the Lungpacer System.
The AeroPace System’s safety information includes intended use, contraindications, warnings, and precautions for diaphragm stimulation therapy.
The AeroPace therapy assists ICU patients with weak diaphragms in regaining strength and reducing ventilator dependence through temporary treatment.
New Journal of Critical Care Medicine study finds AeroPace neurostimulation cuts ventilator days and lowers total episode costs by an estimated $24,000.
Kevin Kearney joins Lungpacer Medical as Chief Commercial Officer, bringing over 20 years of medical device leadership to drive AeroPace System commercialization.
Lungpacer Medical announces the first patient enrollments in the STARI trial, investigating next-generation diaphragm neurostimulation therapy for ventilated patients.
Lungpacer Medical receives FDA IDE approval for the STARI Phase 2 feasibility trial, evaluating the investigational AeroNova System in patients with acute hypoxemic respiratory failure.
Lungpacer Medical submits a premarket approval application to the FDA for the AeroPace System, a diaphragm neurostimulation therapy to help wean patients from mechanical ventilation.
Lungpacer offers career opportunities in medical device innovation for hospital care.
Access AeroPace reimbursement resources from Lungpacer, including expanded Medicare coverage information for broader patient access.
Lungpacer is a medical technology company focused on diaphragm stimulation solutions for hospital-based patient care.
Lungpacer provides product information and team contact for diaphragm stimulation technology.
The Lungpacer System is a medical device designed to stimulate the diaphragm and aid patient care in clinical settings.
Lungpacer Medical Inc. describes how it collects, processes, and protects personal data under GDPR and other regulations.
